HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ciba to offer PURE antimicrobial

This article was originally published in The Rose Sheet

Executive Summary

San Diego, Calif.-based PURE Bioscience has inked a deal with Swiss ingredient supplier Ciba to market and sell PURE's new antimicrobial in the personal-care market, firms announce Dec. 1. Antimicrobial is silver dihydrogen citrate, a stabilized ionic silver compound that formulates readily with other ingredients, firm says. PURE says its patented formula differs from competitors' in that it offers "superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it"; also it is manufactured in an environmentally friendly manner that creates no waste or byproducts. Under the terms of the deal, Ciba holds exclusive marketing rights for personal care under trade name Ciba Tinosan SDC. "With this technology from PURE Bioscience, we are able to support customers in the personal and household care industries as they strive to enhance the antimicrobial effects and shelf life of their formulations," says Catherine Ehrenberger, global head of Ciba Home & Personal Care. "We are especially excited about the opportunities in the cosmetics market, where manufacturers are increasingly expected to deliver antimicrobial benefits without compromising the look and feel of their products." Ciba is one of a number of stakeholders petitioning FDA to finalize its over-the-counter monograph for sunscreens
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS015833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel